201 reports of this reaction
1.6% of all NEOMYCIN SULFATE reports
#11 most reported adverse reaction
MACULAR DEGENERATION is the #11 most commonly reported adverse reaction for NEOMYCIN SULFATE, manufactured by Total Resources International. There are 201 FDA adverse event reports linking NEOMYCIN SULFATE to MACULAR DEGENERATION. This represents approximately 1.6% of all 12,389 adverse event reports for this drug.
Patients taking NEOMYCIN SULFATE who experience macular degeneration should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
MACULAR DEGENERATION is a less commonly reported adverse event for NEOMYCIN SULFATE, but still significant enough to appear in the safety profile.
In addition to macular degeneration, the following adverse reactions have been reported for NEOMYCIN SULFATE:
The following drugs have also been linked to macular degeneration in FDA adverse event reports:
MACULAR DEGENERATION has been reported as an adverse event in 201 FDA reports for NEOMYCIN SULFATE. This does not prove causation, but indicates an association observed in post-market surveillance data.
MACULAR DEGENERATION accounts for approximately 1.6% of all adverse event reports for NEOMYCIN SULFATE, making it a notable side effect.
If you experience macular degeneration while taking NEOMYCIN SULFATE, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.